Synthon (rights of glatiramer acetate)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
The commercialization rights of glatiramer acetate in the United States. It is a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Other Business Products and Services
Acquirer
Primary Office
- P.O. Box 110487
- Research Triangle Park
- Durham, NC 27709
- United States
Synthon (rights of glatiramer acetate) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Synthon (rights of glatiramer acetate)‘s full profile, request access.
Request full access to PitchBook